TY - JOUR
T1 - Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma
T2 - Clinical Experience from an Expanded Access Study in the United States
AU - Pal, Sumanta Kumar
AU - Hoffman-Censits, Jean
AU - Zheng, Hanzhe
AU - Kaiser, Constanze
AU - Tayama, Darren
AU - Bellmunt, Joaquim
N1 - Publisher Copyright:
© 2018 European Association of Urology
PY - 2018/5
Y1 - 2018/5
N2 - Background: Atezolizumab (anti–programmed death-ligand 1) was approved in the USA, Europe, and elsewhere for treatment-naive and platinum-treated locally advanced/metastatic urothelial carcinoma (mUC). Objective: To report efficacy and safety from an atezolizumab expanded access study. Design, setting, and participants: This single-arm, open-label study enrolled 218 patients at 36 US sites. Key eligibility criteria included progression during/following ≥1 platinum-based chemotherapy for mUC or in perioperative setting (progression within 12 mo) and Eastern Cooperative Oncology Group performance status (ECOG PS) 0–2. Intervention: Patients received atezolizumab1200 mg intravenously every 3 wk until loss of clinical benefit, unacceptable toxicity, consent withdrawal, decision to discontinue, death, atezolizumab commercial availability, or study closure. Outcome measurements and statistical analysis: Key end points reported herein included Response Evaluation Criteria in Solid Tumors v1.1 objective response rate and duration, disease control rate (DCR; response or stable disease), and safety. Results and limitations: All patients received prior systemic therapy (68% mUC; 27% adjuvant; and 26% neoadjuvant). At baseline, 57% of 214 treated patients had ECOG PS ≥1, 19% had hemoglobin <10 g/dl, and 25% had liver metastases. Median treatment duration was 9 wk (interquartile range [IQR], 6–12 wk). Median follow-up duration was 2.3 mo (IQR, 1.6–3.4 mo) overall and 2.7 mo (IQR, 2.0–3.5 mo) in patients not known to have died. Seventeen of 114 evaluable patients (15%) had objective responses (16 ongoing at study termination). DCR was 49%. Treatment-related adverse events (mostly fatigue) occurred in 98 of 214 treated patients. Conclusions: The benefit/risk profile of atezolizumab was consistent with that observed in previous studies, despite pretreatment and poor prognostic factors. These results suggest a potential role for atezolizumab in a broader patient range than typically eligible for phase 1–3 studies. Patient summary: In this expanded access study, atezolizumab was active and tolerable in a range of patients with platinum-treated metastatic urothelial carcinoma. In an expanded access study in platinum-treated advanced urothelial carcinoma, the benefit/risk profile of atezolizumab was consistent with previous trials despite a broader patient range than may be typical for phase 1–3 studies.
AB - Background: Atezolizumab (anti–programmed death-ligand 1) was approved in the USA, Europe, and elsewhere for treatment-naive and platinum-treated locally advanced/metastatic urothelial carcinoma (mUC). Objective: To report efficacy and safety from an atezolizumab expanded access study. Design, setting, and participants: This single-arm, open-label study enrolled 218 patients at 36 US sites. Key eligibility criteria included progression during/following ≥1 platinum-based chemotherapy for mUC or in perioperative setting (progression within 12 mo) and Eastern Cooperative Oncology Group performance status (ECOG PS) 0–2. Intervention: Patients received atezolizumab1200 mg intravenously every 3 wk until loss of clinical benefit, unacceptable toxicity, consent withdrawal, decision to discontinue, death, atezolizumab commercial availability, or study closure. Outcome measurements and statistical analysis: Key end points reported herein included Response Evaluation Criteria in Solid Tumors v1.1 objective response rate and duration, disease control rate (DCR; response or stable disease), and safety. Results and limitations: All patients received prior systemic therapy (68% mUC; 27% adjuvant; and 26% neoadjuvant). At baseline, 57% of 214 treated patients had ECOG PS ≥1, 19% had hemoglobin <10 g/dl, and 25% had liver metastases. Median treatment duration was 9 wk (interquartile range [IQR], 6–12 wk). Median follow-up duration was 2.3 mo (IQR, 1.6–3.4 mo) overall and 2.7 mo (IQR, 2.0–3.5 mo) in patients not known to have died. Seventeen of 114 evaluable patients (15%) had objective responses (16 ongoing at study termination). DCR was 49%. Treatment-related adverse events (mostly fatigue) occurred in 98 of 214 treated patients. Conclusions: The benefit/risk profile of atezolizumab was consistent with that observed in previous studies, despite pretreatment and poor prognostic factors. These results suggest a potential role for atezolizumab in a broader patient range than typically eligible for phase 1–3 studies. Patient summary: In this expanded access study, atezolizumab was active and tolerable in a range of patients with platinum-treated metastatic urothelial carcinoma. In an expanded access study in platinum-treated advanced urothelial carcinoma, the benefit/risk profile of atezolizumab was consistent with previous trials despite a broader patient range than may be typical for phase 1–3 studies.
KW - Atezolizumab
KW - Expanded access program
KW - Immunotherapy
KW - Urothelial carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85042289082&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042289082&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2018.02.010
DO - 10.1016/j.eururo.2018.02.010
M3 - Article
C2 - 29478735
AN - SCOPUS:85042289082
SN - 0302-2838
VL - 73
SP - 800
EP - 806
JO - European Urology
JF - European Urology
IS - 5
ER -